Sixth, at the time of writing this manuscript, ALK inhibitors: crizotinib, alectinib; TKIs: osimertinib; immunotherapy: nivolumab, pembrolizumab, durvalumab maintenance were already approved by Czech State Institute for Drug Control as first‐line drugs for treatment of NSCLC in Czechia. The gene discussed is ALK; the disease is non-small cell lung carcinoma.